Opus Genetics, Inc. Common Stock (IRD) is a publicly traded Healthcare sector company. As of May 21, 2026, IRD trades at $4.44 with a market cap of $361.40M and a P/E ratio of -5.42. IRD moved +4.46% today. Year to date, IRD is +108.45%; over the trailing twelve months it is +346.68%. Its 52-week range spans $0.65 to $5.81. Analyst consensus is strong buy with an average price target of $10.58. Rallies surfaces IRD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Opus Genetics Eyes September OPGx-BEST1 Data, Extends Runway Into 2029: Opus Genetics completed enrollment in Cohort 1 of its Phase 1/2 OPGx-BEST1 trial, with three-month data due September 2026, and reported six-month OPGx-LCA5 pediatric results showing 1.5 log unit cone sensitivity gains. FDA accepted LCA5 into its Rare Disease Evidence Principles program and cash runway extends into 2029.
| Metric | Value |
|---|---|
| Price | $4.44 |
| Market Cap | $361.40M |
| P/E Ratio | -5.42 |
| EPS | $-0.80 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.81 |
| 52-Week Low | $0.65 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $14.20M |
| Net Income | $-49.59M |
| Gross Margin | 0.00% |
13 analysts cover IRD: 0 strong buy, 13 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $10.58.